– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks –
– These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma –
-PER-001 improved ocular blood flow, validating target engagement and the sustained release profile of PER-001, enabling a convenient six-month dosing frequency –
– PER-001 was safe and well-tolerated over 24 weeks –
– Company plans to initiate a pivotal-enabling Phase 2b trial in the second half of 2025 –
